High-throughput Autoantibody Analysis in Malignant Pleural Effusion and Tuberculosis Pleural Effusion

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Oct 1

PMID 31567996

Citations 1

Authors

Fengshuang Yi

Xin Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Malignant pleural effusion (MPE) and tuberculosis pleural effusion (TPE) are 2 kinds of common pleural diseases. Finding efficient and accurate biomarkers to distinguish the 2 is of benefit to basic and clinical research. In the present study, we carried out the first high-throughput autoantibody chip to screen the beneficial biomarker with samples of MPE and TPE and the corresponding serum.

Methods: We collected pleural effusion and serum of patients with MPE (n = 10) and TPE (n = 10) who had been in Beijing Chao-Yang hospital from June 2013 to August 2014. Using RayBio Human Protein Array-G2 to measure the concentration of 487 defined autoantibodies.

Results: Fold changes of Bcl-2-like protein 11 (BIM) autoantibody in MPE-serum/TPE-serum and MPE/TPE groups were 10 (P = .019) and 6 (P = .001); for decorin autoantibody, MPE-serum/TPE-serum ratio was 0.6 (P = .029), and MPE/TPE ratio was 0.3 (P < .001).

Conclusion: BIM autoantibody is a promising MPE biomarker by high-throughput autoantibody analysis in MPE and TPE.

Citing Articles

Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model.

Jian J, Fan D, Tian D, Cheng Y, Sun P, Tan C Neurosci Bull. 2022; 38(9):1025-1040.

PMID: 35570231 PMC: 9468199. DOI: 10.1007/s12264-022-00869-y.

References

Leverson J, Zhang H, Chen J, Tahir S, Phillips D, Xue J . Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015; 6:e1590. PMC: 4669759. DOI: 10.1038/cddis.2014.561. View

Win T, Groves A, Phillips G . Antinuclear antibody positive pleural effusion in a patient with tuberculosis. Respirology. 2003; 8(3):396-7. DOI: 10.1046/j.1440-1843.2003.00472.x. View

DeMarshall C, Han M, Nagele E, Sarkar A, Acharya N, Godsey G . Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. Immunol Lett. 2015; 168(1):80-8. DOI: 10.1016/j.imlet.2015.09.010. View

Gyorffy B, Surowiak P, Budczies J, Lanczky A . Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8(12):e82241. PMC: 3867325. DOI: 10.1371/journal.pone.0082241. View

Faber A, Farago A, Costa C, Dastur A, Gomez-Caraballo M, Robbins R . Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A. 2015; 112(11):E1288-96. PMC: 4371986. DOI: 10.1073/pnas.1411848112. View

Porcelijn L, Huiskes E, Oldert G, Schipperus M, Zwaginga J, de Haas M . Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art. Br J Haematol. 2018; 182(3):423-426. DOI: 10.1111/bjh.15404. View

Porcel J, Ordi-Ros J, Esquerda A, Vives M, Madronero A, Bielsa S . Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis. Lupus. 2007; 16(1):25-7. DOI: 10.1177/0961203306074470. View

Damoiseaux J, Andrade L, Fritzler M, Shoenfeld Y . Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev. 2015; 14(6):555-63. DOI: 10.1016/j.autrev.2015.01.017. View

Wang W, Zhou Q, Zhai K, Wang Y, Liu J, Wang X . Diagnostic accuracy of interleukin 27 for tuberculous pleural effusion: two prospective studies and one meta-analysis. Thorax. 2017; 73(3):240-247. DOI: 10.1136/thoraxjnl-2016-209718. View

10.

Porcel J . Malignant pleural effusions because of lung cancer. Curr Opin Pulm Med. 2016; 22(4):356-61. DOI: 10.1097/MCP.0000000000000264. View

11.

Rivera M, Mehta A, Wahidi M . Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e142S-e165S. DOI: 10.1378/chest.12-2353. View

12.

OConnor L, Strasser A, OReilly L, Hausmann G, Adams J, Cory S . Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998; 17(2):384-95. PMC: 1170389. DOI: 10.1093/emboj/17.2.384. View

13.

Liang Q, Shi H, Wang K, Qin S, Qin X . Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med. 2008; 102(5):744-54. DOI: 10.1016/j.rmed.2007.12.007. View

14.

Sionov R, Vlahopoulos S, Granot Z . Regulation of Bim in Health and Disease. Oncotarget. 2015; 6(27):23058-134. PMC: 4695108. DOI: 10.18632/oncotarget.5492. View

15.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

16.

Silosi I, Silosi C, Boldeanu M, Cojocaru M, Biciusca V, Avramescu C . The role of autoantibodies in health and disease. Rom J Morphol Embryol. 2016; 57(2 Suppl):633-638. View

17.

. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000; 162(5):1987-2001. DOI: 10.1164/ajrccm.162.5.ats8-00. View

18.

Trudel S, Li Z, Rauw J, Tiedemann R, Wen X, Stewart A . Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 2007; 109(12):5430-8. DOI: 10.1182/blood-2006-10-047951. View

19.

Gubbiotti M, Vallet S, Ricard-Blum S, Iozzo R . Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 2016; 55:7-21. PMC: 6938589. DOI: 10.1016/j.matbio.2016.09.009. View

20.

Beaudoin S, Gonzalez A . Evaluation of the patient with pleural effusion. CMAJ. 2018; 190(10):E291-E295. PMC: 5849448. DOI: 10.1503/cmaj.170420. View